Risk score for predicting primary cesarean delivery in women with gestational diabetes mellitus

Chadakarn Phaloprakarn* and Siriwan Tangjitgamol

Abstract

Background: Women with gestational diabetes mellitus (GDM) have a higher risk of cesarean delivery (CD) than glucose-tolerant women. The aim of this study was to develop and validate a risk score for predicting primary CD in women with GDM.

Methods: A risk score for predicting primary CD was developed using significant clinical features of 385 women who had a diagnosis of GDM and delivered at our institution between January 2011 and December 2014. The score was then tested for validity in another cohort of 448 individuals with GDM who delivered between January 2015 and December 2018.

Results: The risk score was developed using the features nulliparity, excess gestational weight gain, and insulin use. The scores that classified the pregnant women as low risk (0 points), intermediate risk (1–3 points), and high risk (≥4 points) were directly associated with the primary CD rates of the women in the development cohort: 14.7, 38.2 and 62.3%, respectively (P < 0.001). The model showed good calibration and acceptable discriminative power with a C statistic of 0.724 (95% confidence interval, 0.670–0.777). Similar results were observed in the validation cohort.

Conclusion: A risk score using the features nulliparity, excess gestational weight gain, and insulin use can estimate the risk for primary CD in women with GDM.

Keywords: Gestational diabetes mellitus, Primary cesarean delivery, Risk score

Background

The prevalence of gestational diabetes mellitus (GDM), one of the most common medical disorders of pregnancy, ranged from 1.8 to 25.1% in a previous report [1]. Its prevalence is increasing worldwide in parallel with the increased global prevalence of type 2 diabetes [2]. GDM poses multiple risks to pregnant women and their offspring, such as preeclampsia, macrosomia, and a consequent increase in obstetric interventions involving cesarean delivery (CD) [3, 4]. Several studies have reported that women with GDM have a higher risk of CD, specifically primary CD, than glucose-tolerant women [5–8]. One of the main reasons is to avoid complications associated with macrosomia, including shoulder dystocia and birth trauma. Although there are no current absolute indications for elective CD in women with GDM, standard practice guidelines recommend a scheduled CD when the estimated fetal weight (EFW) is 4500 g or more [9, 10].

Although a cesarean section is a common surgical procedure that can effectively prevent maternal and fetal mortality and morbidity when indicated, the complications of the procedure are well recognized, especially in an emergency setting, and include obstetric hemorrhage, postpartum infection, and the long-term effects of
cesarean section scarring [11, 12]. Hence, the identification of women with GDM who are at risk of primary CD would be useful in clinical practice. For example, clinicians would be aware of the possibility of CD and arrange a better-prepared surgical team for women who require emergency CD to improve surgical outcomes.

Various characteristic features have been identified as risk factors for CD in women with GDM. These include advanced maternal age, nulliparity, obesity, gestational weight gain (GWG) above the Institute of Medicine (IOM) recommendations, and insulin use [6, 8, 13, 14]. In real clinical practice, an obstetrician may be reluctant to proceed with primary CD based on a patient’s individual risk. More solid evidence, obtained by combining these factors into a prediction model, would certainly be useful to support decision making. To date, there have been no studies that have focused on the development of a risk model to predict the likelihood of primary CD in women with GDM. The objective of this study was to develop and validate a risk score that can predict primary CD in women with GDM.

Methods
Development cohort
The risk score was developed in a development cohort comprising all pregnant women who attended our antenatal clinic, had a diagnosis of GDM, and delivered at our institution between January 2011 and December 2014. The exclusion criteria were women who had gestational diabetes, multiple pregnancies, a history of previous uterine surgery (including previous CD and myomectomy), HIV infection, noncephalic presentation, or placental previa.

The sample size for the development of the risk scoring model was determined in accordance with the rule of thumb that a minimum of 10 outcome events are required per predicting factor [15]. We selected 3–5 common features of GDM individuals as predictive factors for primary CD. This would require a minimum of 50 women who had experienced the event to be recruited for the development of the prediction model.

Data from the development cohort were obtained from medical records. These included age, parity, prepregnancy body mass index, GWG, history of diabetes in any first-degree relatives, insulin use (type and dose), the presence or absence of primary CD, indications for primary CD, and neonatal birth weight. Prepregnancy body mass index was categorized into four groups based on the World Health Organization classification: underweight (< 18.5 kg/m²), normal (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²) and obese (≥ 30 kg/m²) [16]. GWG was calculated as the difference in kilograms between the delivery weight and self-reported prepregnancy weight. We classified GWG as above or within/below the IOM recommendations. The recommended ranges of GWG are as follows: 12.5–18.0 kg for underweight women, 11.5–16.0 kg for women of normal weight, 7.0–11.5 kg for overweight women, and 5.0–9.0 kg for obese women [17].

According to our institutional guidelines for GDM screening, pregnant women with any risk factors underwent a glucose challenge test (GCT) at the first visit and were retested at 28–32 weeks of gestation if the first GCT value was normal. On the other hand, all other women without any risk were screened at 24–28 weeks of gestation. Any woman with an abnormal GCT was scheduled for a diagnostic 100-g oral glucose tolerance test. GDM was diagnosed according to the Carpenter and Coustan criteria [18]. Individuals with GDM were treated with diet control with or without insulin treatment based on their blood sugar levels and at the discretion of the endocrinologist. The indications for primary CD included labor dystocia, abnormal or indeterminate fetal heart rate (FHR) tracing, and elective CD due to an estimated large fetus, which was defined as an EFW above the 90th percentile for gestational age [19].

Validation cohort
The risk score was tested in a validation cohort consisting of a different group of singleton pregnant women who attended our antenatal clinic and delivered at our institution between January 2015 and December 2018. The inclusion/exclusion criteria, data collection and risk scoring system for this cohort were the same as those used for the development cohort.

Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics for Windows, Version 22.0 (IBM Corporation, Armonk, NY, USA). Categorical variables are presented as numbers with percentages, and continuous variables are displayed as the medians with interquartile ranges. Categorical variables were compared by the chi-square test or Fisher’s exact test as appropriate. Mann-Whitney U test was used to compare continuous variables. Missing data were handled using multiple imputation. Binary variables were imputed by logistic regression (for two women in the development cohort with missing information about the history of diabetes in any first-degree relatives), whereas continuous variables were imputed by predictive means matching (for one woman in the development cohort and two women in the validation cohort with missing prepregnancy weights). All analyses were performed using imputed complete cases. A P-value < 0.05 was considered statistically significant.

The characteristic features of the development cohort that were associated with primary CD with a P-value < 0.20 in a univariate analysis were included in a
multivariate logistic regression model. To develop a risk scoring system, we followed the methods previously described by Sullivan et al. [20]. In brief, the regression coefficient of each significant variable was divided by the lowest coefficient in the model before being rounded to the nearest integer to obtain the number of points. These score points were summed to derive a total risk score for each woman. The risks for primary CD were according to the total score into low risk, intermediate risk, and high risk.

The performance of the risk score was evaluated in terms of both discrimination and calibration. Discrimination (that is, the ability of the prediction model to differentiate between women who undergo primary CD and those who do not) was assessed using the C statistic or area under the receiver operating characteristic curve [21]. Calibration was evaluated by a calibration plot of observed probability versus predicted probability, which was grouped according to the quartile of predicted probability. The Hosmer-Lemeshow goodness-of-fit test was also used for calibration [22]. A value of $P > 0.05$ derived from this test was accepted as good calibration.

Ethical approval for the study was granted by the Vajira Institution Review Board (certificate of approval no.138/2561). This study is reported in line with the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement [23].

**Results**

**Development cohort**

From January 2011 to December 2014, 492 singleton pregnant women with GDM delivered at our institution. Of these, 107 women were excluded for certain reasons, as shown in Fig. 1. A total of 385 women were finally included in the development cohort.

The characteristic features of the women in the development cohort are presented in Table 1. The prevalence of primary CD in this cohort was 33.8%. The most common indication for primary CD was emergency CD due to labor dystocia (70.0%), followed by elective CD due to an estimated large fetus (23.8%) and emergency CD due to abnormal FHR tracing (6.2%). Rates of nulliparity, GWG above the IOM recommendations, and insulin use were higher in the women who...
underwent primary CD than in the women who did not. These three features were identified as significant predictors of primary CD in both the univariate and multivariate analyses (Table 2). The regression coefficient values were 1.531 for nulliparity, 0.547 for GWG above the IOM recommendations, and 0.899 for insulin use. These coefficients were divided by 0.547 (the lowest value among the three) and then rounded to the nearest integer. The total score of each woman varied from 0 to 6 points (Table 2).

The receiver operating characteristic curve of the risk score yielded a C statistic of 0.724 (95% confidence interval, 0.670–0.777), indicating acceptable discriminatory power (Fig. 2). The calibration plot is presented in Fig. 3. The model displayed good calibration with no apparent under- or overprediction. The Hosmer-Lemeshow test demonstrated a good model fit, with a P-value of 0.929. We classified the score points of the women in the development cohort into three categories to enhance the clinical utility of the risk model: low risk (0 points),

| Table 1 | Characteristics of the women in the development and validation cohorts |
|-----------------|------------------|-----------------|------------------|------------------|
| Characteristic | Development cohort (n = 385) | P | Validation cohort (n = 448) | P |
|-----------------|------------------|-----------------|------------------|------------------|
| Number of women | 130 | 255 | 178 | 270 |
| Age (years), median (IQR) | 31.5 (27.0–35.0) | 31.0 (27.0–36.0) | 0.766 | 33.0 (28.0–36.0) | 31.0 (27.0–35.0) | 0.093 |
| Age (years), n (%) | 0.372 | 0.054 |
| < 35 | 92 (70.8) | 169 (66.3) | 109 (61.2) | 189 (70.0) |
| ≥ 35 | 38 (29.2) | 86 (33.7) | 69 (38.8) | 81 (30.0) |
| Parity, n (%) | < 0.001 | < 0.001 |
| Multiparity | 45 (34.6) | 180 (70.6) | 57 (32.0) | 179 (66.3) |
| Nulliparity | 85 (65.4) | 75 (29.4) | 121 (68.0) | 91 (33.7) |
| Prepregnancy BMI category (kg/m^2), n (%) | 0.301 | 0.478 |
| Normal | 74 (56.9) | 150 (58.8) | 83 (46.6) | 139 (51.5) |
| Underweight | 7 (5.4) | 26 (10.2) | 18 (10.1) | 31 (11.5) |
| Overweight | 33 (25.4) | 51 (20.0) | 51 (28.7) | 60 (22.2) |
| Obese | 16 (12.3) | 28 (11.0) | 26 (14.6) | 40 (14.8) |
| Gestational weight gain, n (%) | 0.003 | < 0.001 |
| Within/below IOM recommendations | 78 (60.0) | 190 (74.5) | 105 (59.0) | 214 (79.3) |
| Above IOM recommendations | 52 (40.0) | 65 (25.5) | 73 (41.0) | 56 (20.7) |
| History of diabetes in a first-degree relative, n (%) | 0.271 | 0.992 |
| No | 90 (69.2) | 190 (74.5) | 126 (70.8) | 191 (71.7) |
| Yes | 40 (30.8) | 65 (25.5) | 52 (29.2) | 79 (29.3) |
| Insulin use, n (%) | 0.044 | 0.045 |
| No | 108 (83.1) | 230 (90.2) | 148 (83.1) | 242 (89.6) |
| Yes | 22 (16.9) | 25 (9.8) | 30 (16.9) | 28 (10.4) |
| Type of insulin, n (%) | 0.397 | 0.084 |
| Rapid-acting insulin | 3 (2.3) | 3 (1.2) | 5 (2.8) | 2 (0.7) |
| Short-acting insulin | 8 (6.2) | 7 (2.7) | 10 (3.4) | 3 (1.1) |
| Intermediate-acting insulin | 8 (6.2) | 2 (0.8) | 6 (3.4) | 10 (3.7) |
| Premixed insulin | 11 (8.5) | 19 (7.5) | 17 (9.6) | 20 (7.4) |
| Units of insulin used in pregnancy, median (IQR) | 545 (256–1641) | 456 (271–1622) | 1.000 | 1029 (287–1747) | 984 (387–2221) | 0.785 |
| Indication for primary CD, n (%) | 0.001 | < 0.001 |
| Elective CD due to an estimated large fetus | 31 (23.8) | – | – | 57 (32.0) | – | – |
| Emergency CD due to labor dystocia | 91 (70.0) | – | – | 112 (62.9) | – | – |
| Emergency CD due to abnormal FHR tracing | 8 (6.2) | – | – | 9 (5.1) | – | – |
| Neonatal birth weight (g), median (IQR) | 3582 (3356–3882) | 3108 (2845–3374) | < 0.001 | 3647 (3449–3880) | 3062 (2821–3346) | < 0.001 |

**BMI** Body mass index, **CD** Cesarean delivery, **FHR** Fetal heart rate, **IOM** Institute of Medicine, **IQR** Interquartile range

The receiver operating characteristic curve of the risk score yielded a C statistic of 0.724 (95% confidence interval, 0.670–0.777), indicating acceptable discriminatory power (Fig. 2). The calibration plot is presented in Fig. 3. The model displayed good calibration with no apparent under- or overprediction. The Hosmer-Lemeshow test demonstrated a good model fit, with a P-value of 0.929. We classified the score points of the women in the development cohort into three categories to enhance the clinical utility of the risk model: low risk (0 points),
intermediate risk (1–3 points), and high risk (≥ 4 points). This classification resulted in the assignment of 143 (37.2%) women to the low-risk category, 173 (44.9%) women to the intermediate-risk category, and 69 (17.9%) women to the high-risk category (Table 3). The rates of primary CD in the women were 14.7, 38.2, and 62.3%, respectively. The risk of primary CD was positively associated with the total score (P for trend < 0.001).

Validation cohort
From a database of 591 singleton pregnant women with GDM who delivered at our institution between January 2015 and December 2018, a total of 448 women who met the same inclusion/exclusion criteria as the development cohort were selected into the validation cohort (Fig. 1). Primary CD was observed in 39.7% of the women in this cohort. The significant factors associated with primary CD observed in the validation cohort were similar to those found in the development cohort (Table 1).

The C statistic of the risk score was 0.726 (95% confidence interval, 0.678–0.774) (Fig. 2). The calibration plot for the validation cohort showed reasonable calibration, as depicted in Fig. 3. The Hosmer-Lemeshow P-value was 0.250, indicating good calibration.

When the categorization of the score points was applied to the validation cohort, the results were similar to

| Predictor | Crude OR (95% CI) | Adjusted OR* (95% CI) | Coefficient | Points b |
|-----------|------------------|-----------------------|-------------|---------|
| Parity    |                  |                       |             |         |
| Multiparity | 1.00             | 1.00                  | Reference   | 0       |
| Nulliparity | 4.12 (2.27–7.47) | 4.62 (2.91–7.36)      | 1.531       | 3       |
| Gestational weight gain | |                       |             |         |
| Within/below IOM recommendations | 1.00 | 1.00 | Reference | 0       |
| Above IOM recommendations | 1.95 (1.23–3.06) | 1.73 (1.06–2.81) | 0.547 | 1       |
| Insulin use |                  |                       |             |         |
| No | 1.00 | 1.00 | Reference | 0       |
| Yes | 1.87 (1.01–3.47) | 2.46 (1.25–4.84) | 0.899 | 2       |

CI Confidence interval, OR Odds ratio, IOM Institute of Medicine

*Adjusted for the other variables in the table. bA point was allocated to each variable according to its coefficient value. Each coefficient was divided by 0.547 (the lowest coefficient among the significant predictors, corresponding to gestational weight gain above recommendations) and rounded to the nearest integer.

![ROC Curve](image1.png)

**A. Development cohort**

![ROC Curve](image2.png)

**B. Validation cohort**

*Fig. 2* Receiver operating characteristic curves of the risk score for the prediction of primary cesarean delivery in the development (a) and validation (b) cohorts.
those for the development cohort: 149 (33.2%) women were assigned to the low-risk category, 218 (48.7%) women to the intermediate-risk category, and 81 (18.1%) women to the high-risk category (Table 3). There was a positive association of the primary CD risk with the risk category ($P$ for trend < 0.001). The primary CD rates for the low-, intermediate-, and high-risk categories were 18.8, 39.9, and 77.8%, respectively (Table 3).

**Discussion**

Primary CD, both elective and emergency CD, is commonly encountered in women with GDM. Current international practice guidelines recommend elective CD in women with GDM who have an EFW of 4500 g or more in order to reduce complications from difficult vaginal delivery [9, 10]. Aside from elective CD, emergency CD is also increased in GDM due to a higher chance of abnormal FHR patterns compared to glucose-tolerant women [24]. Our study focused on these two conditions of large fetuses and abnormal FHR tracings in an assessment of unfavorable impacts of GDM.

We developed and externally validated a simple prediction model for primary CD in two different groups of women with GDM (development and validation cohorts) who attended our antenatal clinic under similar conditions. The proposed risk score showed acceptable discriminatory power (C statistic of 0.724) and was clearly supported by external validation (C statistic of 0.726). The Hosmer-Lemeshow test indicated good calibration without a difference of predictive power between the development and validation cohorts ($P$ > 0.05). To our knowledge, this is the first risk scoring system to be developed and validated for the identification of primary CD in individuals with GDM using only basic clinical data.

The three risk factors for primary CD in our risk scoring system, in descending order of importance, were nulliparity, insulin use, and GWG above the IOM recommendations.

| Table 3 Risk of primary cesarean delivery in the development and validation cohorts according to risk category |
|---------------------------------------------------------------------------------------------------------|
| **Risk category** | **Development cohort (n = 385)** | **Validation cohort (n = 448)** |
| | Total number of women | Number of women who underwent primary CD (%) | Total number of women | Number of women who underwent primary CD (%) |
| Low (0 points) | 143 | 21/143 (14.7) | 149 | 28/149 (18.8) |
| Intermediate (1–3 points) | 173 | 66/173 (38.2) | 218 | 87/218 (39.9) |
| High (≥ 4 points) | 69 | 43/69 (62.3) | 81 | 63/81 (77.8) |

CD Cesarean delivery
These three variables were also identified as factors that were significantly associated with primary CD in previous studies [8, 13, 14]. The adjusted odds ratio of 4.62 for nulliparity as a risk factor for primary CD that was demonstrated in our study was comparable to the finding of Gascho et al. [13], who also reported a 4.6-fold-greater odds of primary CD for nulliparous pregnant women with GDM. Likewise, the 1.46-fold risk of primary CD among the women who were treated with insulin (108/338 women or 46.8%) compared to the women without insulin treatment (22/47 women or 32.0%) observed in our study was similar to the relative risk of primary CD of 1.48 among insulin-treated pregnant women with GDM (24.7%) compared to those without insulin therapy (16.7%) found in the study of Ehrenberg et al. [8]. Regarding GWG, Cheng et al. [14] found that the risk of primary CD was increased by 1.52 fold among individuals with GDM whose weight gain exceeded the IOM guidelines compared to women with a GWG within the guidelines. This odds ratio was slightly lower than the odds ratio of 1.73 observed in the present study, which compared women with a GWG above the IOM recommendations with those whose GWG was within/below the recommendations.

Of the three identified risk factors for primary CD, GWG above the IOM recommendations appeared to be a modifiable risk factor. Preventive measures to reduce the likelihood of excessive GWG may lower the risk of primary CD. This goal could be achieved through a strict diet and a planned target weight gain throughout pregnancy [25–27].

Our risk score had a moderate degree of accuracy for classifying women with GDM into low, intermediate, and high risk categories for primary CD. In the development cohort, 43 out of 69 women who were classified as being at high risk for primary CD ended up having CD, giving a positive predictive value of 62.3% and a negative predictive value of 72.5%. In the validation cohort, the positive predictive value and negative predictive value of the risk score for primary CD among women who were classified into the high-risk category were 77.8 and 68.7%, respectively. Categorizing individuals with GDM into different risk categories would allow clinicians to thoroughly inform pregnant women about their estimated risk of primary CD. This could also alert attending staff for the proactive early detection of intrapartum conditions that lead to CD, including labor dystocia and abnormal FHR tracing, in women at high risk.

We were aware of a few limitations of the study. Being a retrospective study, some data that might contribute to the risk of primary CD were not available or incomplete, for example, glucose control status, the presence or absence of polyhydramnios, fetal abdominal circumference, and EFW. However, we believe that the small number of features (with satisfactory results) certainly makes the risk tool simpler for clinical application. Further, the rule of thumb for sample size calculation was unable to consider the magnitude of predictor effects and distribution of predictors. Hence, the clinicians who would apply this in clinical practice must be aware of this limitation. In addition, the points for each variable were converted from the original regression coefficients to integers. This conversion could lead to some loss in predictive accuracy. Another limitation was the similar characteristics of the development and validation cohorts (that is, pregnant women seeking medical care at the same hospital and country). Additional external validation using cohorts in different settings is required to confirm the performance and generalizability of the model. Last, although the risk score can help in predicting the risk of CD, it can also lead to maternal anxiety. Hence, clinicians should realize its advantages and disadvantages when applying the risk score in clinical practice.

Our study has several strengths. First, the sample size of the development cohort was adequate to build a reliable and robust model. Second, a multiple imputation technique was applied to handle missing data to maintain the statistical power and unbiased results. Third, the sample size of the validation cohort was also adequate (meeting the requirement of a minimum of 100 events and/or 100 nonevents) [28] to support its generalizability. The concordant results between the development and validation cohorts suggested the reliability of the model. Last, the risk score is a novel but simple approach that includes only basic characteristic features of pregnant women and uses a points system that can readily estimate the risk at a glance.

Conclusion
We developed a new risk score using three characteristic features to predict primary CD in women with GDM. The score was well validated with high reliability. Risk stratification based on the score could help clinicians assess the chance of primary CD in each woman with certainty. The application of the model should guide attending staff in closely monitoring women at high risk for primary CD. Proactive early detection with the management of some modifiable risk factors, through, for example, strict dietary and weight control, may reduce the risk of primary CD in women with GDM and improve obstetric outcomes.

Abbreviations
CD: Cesarean delivery; EFW: Estimated fetal weight; FHR: Fetal heart rate; GCT: Glucose challenge test; GDM: Gestational diabetes mellitus; GWG: Gestational weight gain; HIV: Human immunodeficiency virus; IOM: Institute of Medicine; TRIPOD: Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis
Acknowledgements
Not Applicable.

Authors’ contributions
CP: study design, data collection and interpretation, manuscript writing, proof and validation; and ST: manuscript writing, proof and validation. All authors have critically revised the manuscript and approved the final version.

Funding
This work was supported by the Navamindradhiraj University Research Fund.

Availability of data and materials
The datasets used and analyzed in this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Vajira Institution Review Board (certificate of approval no.138/2561). Permission to access the data was granted by the dean of the Faculty of Medicine Vajira Hospital.

Consent for publication
Not Applicable.

Competing interests
All authors declare that they have no competing interest.

Received: 22 June 2020 Accepted: 2 October 2020
Published online: 08 October 2020

References
1. Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr Diab Rep. 2016;16:7.
2. Moon JH, Kwak SH, Jang HC. Prevention of type 2 diabetes mellitus in women with previous gestational diabetes mellitus. Korean J Intern Med. 2017;32:26–41.
3. Billonnet C, Mitanchez D, Weill A, Nizard J, Alla F, Hartemann A, et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. Diabetologia. 2017;60:636–44.
4. Waters TP, Dyer AR, Scholtens DM, Dooley SL, Herer E, Lowe LP, et al. Maternal and neonatal morbidity for women who would be added to the diagnosis of GDM using IADPSG criteria: a secondary analysis of the hyperglycemia and adverse pregnancy outcome study. Diabetes Care. 2016;39:204–10.
5. Heddenson MW, Xu F, Sridhar SB, Han ES, Quesenberry CP, Crites Y. A cohort study of maternal cardiometabolic risk factors and primary cesarean delivery in an integrated health system. PLoS One. 2018;13:e0199992.
6. Gonçalves E, Barros M, Namora G, Magalhães A, Rodrigues T, et al. Gestational diabetes mellitus: a risk factor for non-elective cesarean section. J Obstet Gynaecol Res. 2012;38:154–9.
7. Bironbohninsam D, Waiyanikorn R. Emergency cesarean section rate between women with gestational diabetes and normal pregnant women. Taiwan J Obstet Gynecol. 2016;55:64–7.
8. Ehrenberg HM, Durnwald CP, Catalano P, Mercer BM. The influence of obesity and diabetes on the risk of cesarean delivery. Am J Obstet Gynecol. 2004;191:969–74.
9. Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131:e49–64.
10. Garabedian C, Deruelle P. Delivery (timing, route, peripartum glycemic control) in women with gestational diabetes mellitus. Diabetes Metab. 2010;36(6 Pt 2):155–21.
11. American College of Obstetricians and Gynecologists (College), Society for Maternal-Fetal Medicine, Caughey AB, Cahill AG, Guise JM, Rouse DJ. Safe prevention of the primary cesarean delivery. Am J Obstet Gynecol. 2014;210:179–93.
12. Xu C, Fu Q, Tao HB, Lin XJ, Wang ML, Xia SX, et al. Effect of cesarean section on the severity of postpartum hemorrhage in Chinese women: the Shanxi study. Curr Med Sci. 2018;38:618–25.
13. Gascho CL, Leandro DM, Ribeiro E, Silva T, Silva JC. Predictors of cesarean delivery in pregnant women with gestational diabetes mellitus. Rev Bras Ginecol Obstet. 2017;39:60–5.
14. Cheng YW, Chung JH, Kurbisch-Block I, Inturrisi M, Shafer S, Caughey AB. Gestational weight gain and gestational diabetes mellitus: perinatal outcomes. Obstet Gynecol. 2008;112:1015–22.
15. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.
16. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000(894–xii):1–25.
17. Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines. In: Rasmussen KM, Yaktine AL, editors. Weight gain during pregnancy: reexamining the guidelines. Washington (DC): National Academies Press (US); 2009.
18. Carpenter MW, Couson DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144:768–73.
19. Borisut P, Kovavisarach E. Standard intrauterine growth curve of Thai neonates delivered at Rajavithi hospital. J Med Assoc Thai. 2014;97:798–803.
20. Sullivan LM, Massaro JM, D’Agostino RB Sr. Presentation of multivariante data for clinical use: the Framingham study risk score functions. Stat Med. 2004;23:1631–60.
21. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem. 2008;54:17–23.
22. Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. New York: Wiley; 2013.
23. Collins GS, Retisma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BLOM. 2015;122:434–43.
24. Buscicchio G, Gentilucci L, Giannubilo SR, Tranquilli AL. Computerized analysis of fetal heart rate in pregnancies complicated by gestational diabetes mellitus. Gynecol Endocrinol. 2010;26:270–4.
25. Hernandez TL, Brand-Miller JC. Nutrition therapy in gestational diabetes mellitus: time to move forward. Diabetes Care. 2018;41:1343–5.
26. Harrison AL, Shields N, Taylor NF, Frawley HC. Exercise improves glycaemic control in women diagnosed with gestational diabetes mellitus: a systematic review. J Physiother. 2016;62:188–96.
27. Wang C, Zhu W, Wei Y, Feng H, Su R, Yang H. Exercise intervention during pregnancy can be used to manage weight gain and improve pregnancy outcomes in women with gestational diabetes mellitus. BMC Pregnancy Childbirth. 2015;15:255.
28. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35:214–26.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.